Advertisement

Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease

  • Carl AmilonEmail author
  • Mohammad Niazi
  • Anders Berggren
  • Magnus Åstrand
  • Bengt Hamrén
Original Research Article
  • 45 Downloads

Abstract

Background and Objective

Ticagrelor, a reversible P2Y12 platelet inhibitor, is under investigation as a sickle cell disease (SCD) therapy in children. HESTIA1 (NCT02214121) was the first ticagrelor study generating pharmacokinetic (PK), pharmacodynamic (PD, P2Y12 reactivity units [PRU]), and safety data in 45 pediatric SCD patients. Population PK and PK/PD relationships for ticagrelor were quantified using a PK approach.

Methods

An adult population PK model was refined to describe ticagrelor and AR–C124910XX (active metabolite) plasma concentration and time data over a wide range of single/repeated ticagrelor doses (0.125–2.25 mg/kg). Population PK/PD modeling was used to describe the time course and extent of platelet inhibition. Demographic covariate relationships were investigated.

Results

The final population PK model adequately described ticagrelor and AR-C124910XX plasma concentrations over time. An allometric body weight relationship between ticagrelor and AR-C124910XX clearances and volumes of distribution was used. Significant covariates for ticagrelor were sex (relative bioavailability) and cholecystectomy (central volume of distribution). Estimated oral clearances (35 kg patient; median bodyweight) were 22.8 L/h (ticagrelor) and 9.97 L/h (AR-C124910XX). The final population PK/PD model well-described the time course and extent of platelet inhibition. Estimated baseline PRU was 283, maximum PRU effect was fixed at 1, and the ticagrelor concentration for half-maximum PRU effect was 233 nmol/L.

Conclusions

These analyses offer the first quantitative characterization of the dose-exposure-response relationship for ticagrelor in pediatric SCD patients. This model-based approach may be used to inform dose selection and design of subsequent studies that aim to define ticagrelor safety and efficacy in pediatric SCD patients.

Notes

Acknowledgments

The authors would like to acknowledge Jessica Persson (AstraZeneca, Gothenburg, Sweden) for dataset programming support, and also Jackie Phillipson from Zoetic Science (Macclesfield, UK), who provided medical writing support (outline, all drafts, assembling tables and figures, collating author comments, grammatical editing and referencing); this support was funded by AstraZeneca.

Compliance with Ethical Standards

Conflicts of interest

Carl Amilon, Mohammad Niazi, Anders Berggren, Magnus Åstrand, and Bengt Hamrén are employees of AstraZeneca and also hold stocks/shares in AstraZeneca.

Ethics

Prior to the start of any study-related procedures, signed informed consent was obtained from the parent(s)/legal guardian, and assent/consent was obtained from each child/adolescent. The final study protocol, amendments, and informed consent documentation were approved by an Ethics Committee and/or Institutional Review Board. HESTIA1 was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization/Good Clinical Practice Guidelines, and followed applicable regulatory requirements and the AstraZeneca policy on bioethics.

Funding

This study and analyses were funded by AstraZeneca.

Supplementary material

40262_2019_758_MOESM1_ESM.docx (717 kb)
Supplementary material 1 (DOCX 718 kb)

References

  1. 1.
    Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.CrossRefGoogle Scholar
  2. 2.
    Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–800.CrossRefGoogle Scholar
  3. 3.
    Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27:259–74.CrossRefGoogle Scholar
  4. 4.
    van Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7:1556–65.CrossRefGoogle Scholar
  5. 5.
    Nylander S, Schulz R. Effects of P2Y12 receptor antagonists beyond platelet inhibition – comparison of ticagrelor with thienopyridines. Br J Pharmacol. 2016;173:1163–78.CrossRefGoogle Scholar
  6. 6.
    Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of Equilibrative Nucleoside Transporter 1. J Cardiovasc Pharmacol Ther. 2014;19:209–19.CrossRefGoogle Scholar
  7. 7.
    Nylander S, Femia EA, Scavone M, Berntsson P, Asztély AK, Nelander K, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost. 2013;11:1867–76.Google Scholar
  8. 8.
    Teng R. Ticagrelor: pharmacokinetic, pharmacodynamic and pharmacogenetic profile: an update. Clin Pharmacokinet. 2015;54:1125–38.CrossRefGoogle Scholar
  9. 9.
    Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol. 2010;70:65–77.CrossRefGoogle Scholar
  10. 10.
    Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010;66:487–96.CrossRefGoogle Scholar
  11. 11.
    Teng R, Mitchell PD, Butler K. Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. J Clin Pharm Ther. 2012;37:464–8.CrossRefGoogle Scholar
  12. 12.
    Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011;39:703–10.CrossRefGoogle Scholar
  13. 13.
    van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005;31:195–204.CrossRefGoogle Scholar
  14. 14.
    Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038–47.CrossRefGoogle Scholar
  15. 15.
    Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38:1514–21.CrossRefGoogle Scholar
  16. 16.
    Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–85.CrossRefGoogle Scholar
  17. 17.
    Li J, Tang W, Storey RF, Husted S, Teng R. Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. Int J Clin Pharmacol Ther. 2016;54:666–74.CrossRefGoogle Scholar
  18. 18.
    Röshammar D, Bergstrand M, Andersson T, Storey RF, Hamrén B. Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction. Int J Clin Pharmacol Ther. 2017;55:416–24.CrossRefGoogle Scholar
  19. 19.
    Åstrand M, Amilon C, Röshammar D, Himmelmann A, Angiolillo DJ, Storey RF, et al. Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. Br J Clin Pharmacol. 2019;85:413–21.CrossRefGoogle Scholar
  20. 20.
    Ware RE, de Montalembert M, Tshiolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390:311–23.CrossRefGoogle Scholar
  21. 21.
    Novelli EM, Gladwin MT. Crises in sickle cell disease. Chest. 2016;149:1082–93.CrossRefGoogle Scholar
  22. 22.
    Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–48.CrossRefGoogle Scholar
  23. 23.
    Kavanagh PL, Sprinz PG, Vinci SR, Bauchner H, Wang CJ. Management of children with sickle cell disease: a comprehensive review of the literature. Pediatrics. 2011;128:e1552–74.CrossRefGoogle Scholar
  24. 24.
    Ataga KI, Stocker J. The trials and hopes for drug development in sickle cell disease. Br J Haematol. 2015;170:768–80.CrossRefGoogle Scholar
  25. 25.
    Noubouossie D, Key NS, Ataga KI. Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev. 2016;30:245–56.CrossRefGoogle Scholar
  26. 26.
    Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med. 1997;129:507–16.CrossRefGoogle Scholar
  27. 27.
    Bennewitz MF, Jimenez MA, Vats R, Tutuncuoglu E, Jonassaint J, Kato GJ, et al. Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli. JCI Insight. 2017;2:e89761.CrossRefGoogle Scholar
  28. 28.
    Cabannes R, Lonsdorfer J, Castaigne JP, Ondo A, Plassard A, Zohoun I. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents Actions Suppl. 1984;15:199–212.Google Scholar
  29. 29.
    Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med. 2016;374:625–35.CrossRefGoogle Scholar
  30. 30.
    Jakubowski JA, Hoppe CC, Zhou C, Smith BE, Brown PB, Heath LE, et al. Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. Thromb Haemost. 2017;117:580–8.CrossRefGoogle Scholar
  31. 31.
    Hsu LL, Sarnaik S, Williams S, Amilon C, Wissmar J, Berggren A, on behalf of the HESTIA-1 Investigators. A dose-ranging study of ticagrelor in children aged 3–17 years with sickle cell disease: a two-part phase 2 study. Am J Hematol. 2018;93:1493–500.CrossRefGoogle Scholar
  32. 32.
    Vinks AA. Important role of population pharmacokinetic/pharmacodynamic modeling in pediatric therapeutics. J Pediatr. 2011;159:361–3.CrossRefGoogle Scholar
  33. 33.
    Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2299–306.CrossRefGoogle Scholar
  34. 34.
    Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481–504.CrossRefGoogle Scholar
  35. 35.
    Xu XS, Dunne A, Kimko H, Nandy P, Vermeulen A. Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2011;38:423–32.CrossRefGoogle Scholar
  36. 36.
    Bergstrand M, Karlsson MO. Handling data below the limit of quantification in mixed effect models. AAPS J. 2009;11:371–80.CrossRefGoogle Scholar
  37. 37.
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidelines E11: Clinical investigation of medicinal products in the paediatric population. June 2000. http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/clinical-investigation-of-medicinal-products-in-the-pediatric-population.html. Accessed 5 Nov 2018.
  38. 38.
    Food and Drug Administration. Guidance for industry: population pharmacokinetics. February 1999. https://www.fda.gov/downloads/drugs/guidances/UCM072137.pdf. Accessed 5 Nov 2018.
  39. 39.
    European Medicines Agency. Guidance on reporting the results of population pharmacokinetic analyses. June 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003067.pdf. Accessed 5 Nov 2018.
  40. 40.
    Jonsson EN, Karlsson MO. Xpose–an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Progr Biomed. 1999;58:51–64.CrossRefGoogle Scholar
  41. 41.
    Anderson BJ, van Lingen RA, Hansen TG, Lin YC, Holford NH. Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology. 2002;96:1336–45.CrossRefGoogle Scholar
  42. 42.
    West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276:122–6.CrossRefGoogle Scholar
  43. 43.
    Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–51.CrossRefGoogle Scholar
  44. 44.
    Rousseau A, Léger F, Le Meur Y, Saint-Marcoux F, Paintaud G, Buchler M, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit. 2004;26:23–30.CrossRefGoogle Scholar
  45. 45.
    Marsousi N, Samer CF, Fontana P, Reny JL, Rudaz S, Desmeules JA, et al. Coadministration of ticagrelor and ritonavir: toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clin Pharmacol Ther. 2016;100:295–304.CrossRefGoogle Scholar
  46. 46.
    Ojodu J, Hulihan MM, Pope SN, Grant AM, Centers for Disease Control and Prevention (CDC). Incidence of sickle cell trait—United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63:1155–8.Google Scholar
  47. 47.
    Anderson BJ, Larsson P. A maturation model for midazolam clearance. Paediatr Anaesth. 2011;21:302–8.CrossRefGoogle Scholar
  48. 48.
    Söderlund F, Asztély A-K, Jeppsson A, Nylander S, Berggren A, Nelander K, et al. In vitro anti-platelet potency of ticagrelor in blood samples from infants and children. Thromb Res. 2015;136:620–4.CrossRefGoogle Scholar
  49. 49.
    Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261–73.CrossRefGoogle Scholar
  50. 50.
    Moser BA, LaBell ES, Chigutsa E, Jakubowski JA, Small DS. Population pharmacokinetic and exposure-response analyses of prasugrel in pediatric patients with sickle cell anemia. Clin Pharmacokinet. 2018;57:243–5.CrossRefGoogle Scholar
  51. 51.
    Kanter J, Abboud M, Kaya B, Nduba V, Amilon C, Gottfridsson C, et al. Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study. Br J Haematol. 2019;184:269–78.CrossRefGoogle Scholar
  52. 52.
    Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376:429–39.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech UnitAstraZenecaGothenburgSweden
  2. 2.Global Medicines DepartmentAstraZenecaGothenburgSweden

Personalised recommendations